Shanghai, China BioVeda China Fund appeared to be the VC, which was created in 2005. The venture was found in Asia in China. The main department of described VC is located in the Shanghai.
The fund has no exact preference in some founders of portfolio startups. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight ASLAN Pharmaceuticals, DiaCarta, CARsgen Therapeutics. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Biotechnology. For fund there is no match between the location of its establishment and the land of its numerous investments - United States.
This organization was formed by ZHI YANG. Besides them, we counted 5 critical employees of this fund in our database.
The top activity for fund was in 2014. This BioVeda China Fund works on 1 percentage points more the average amount of lead investments comparing to the other organizations. Speaking about the real fund results, this VC is 50 percentage points more often commits exit comparing to other organizations. The increased amount of exits for fund were in 2019. The fund is generally included in less than 2 deals every year. The common things for fund are deals in the range of 50 - 100 millions dollars.
The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the BioVeda China Fund, startups are often financed by Morningside Group, BioVeda Capital, Sanofi. The meaningful sponsors for the fund in investment in the same round are SDIC Venture Capital, New Horizon Capital, Morningside Group. In the next rounds fund is usually obtained by KTB Ventures, Jolly Innovation Ventures, 3E Bioventures.
Related Funds
Funds with similar focus
| Fund Name | Location |
| 6Rooms | China, Shanghai |
| Accenture | County Dublin, Dublin, Ireland |
| another.vc | Berlin, Berlin, Germany |
| Cognitive Investment | Seoul, Seoul-t'ukpyolsi, South Korea |
| Emerge Ventures, Singapore | Central, Central Region, Singapore |
| Global Investment Technologies | New York, New York, United States |
| Green Dot | California, Pasadena, United States |
| Growth Source Financial Technologies | India, Maharashtra, Mumbai |
| Huis Ten Bosch | Chiba Prefecture, Futtsu, Japan |
| Klinkert Investment Trust | - |
| London School of Economics and Political Science (LSE) | England, London, United Kingdom |
| Matrix | Herzliya, Israel, Tel Aviv |
| Ogaki Kyoritsu Bank | Gifu Prefecture, Japan, Ogaki |
| Scopelec | France, Revel, Rhone-Alpes |
| Sesame Street | Alabama, America, United States |
| Standard Industries | New York, New York, United States |
| startGBC | Canada, Ontario, Toronto |
| TripleTree | Minneapolis, Minnesota, United States |
| Valor | Ena, Gifu Prefecture, Japan |
| Yaba Ziguan | China, Qingpu, Shanghai |
Discover 4 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Cellenkos | $15M | 04 Nov 2021 | Houston, Texas, United States | ||
Oculis | $57M | 04 May 2021 | Iceland, Iceland | ||
| $56M | 09 Feb 2021 | Shanghai, China | |||
Boan Biotech | $105M | 05 Jan 2021 | Yantai, Liaoning, China | ||
Seinda | 23 Sep 2020 | Guangzhou, Guangdong, China | |||
BioNTech | $325M | 09 Jul 2019 | Mainz, Rheinland-Pfalz, Germany | ||
Eucure Biopharma | $10M | 01 Jul 2017 | Beijing | ||
Eucure Biopharma | $9M | 31 Dec 2016 | Beijing | ||
ASLAN Pharmaceuticals | $34M | 07 Dec 2015 | Singapore, Central Region, Singapore |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Cellenkos | $15M | 04 Nov 2021 | Houston, Texas, United States | ||
Oculis | $57M | 04 May 2021 | Iceland, Iceland | ||
| $56M | 09 Feb 2021 | Shanghai, China | |||
Boan Biotech | $105M | 05 Jan 2021 | Yantai, Liaoning, China | ||
Seinda | 23 Sep 2020 | Guangzhou, Guangdong, China | |||
BioNTech | $325M | 09 Jul 2019 | Mainz, Rheinland-Pfalz, Germany | ||
Eucure Biopharma | $10M | 01 Jul 2017 | Beijing | ||
Eucure Biopharma | $9M | 31 Dec 2016 | Beijing | ||
ASLAN Pharmaceuticals | $34M | 07 Dec 2015 | Singapore, Central Region, Singapore |
